Elucent Medical, a medical technology company headquartered in Eden Prairie and focused on the field of surgical navigation, recently successfully completed a $42.5 million Series C funding round.
The funding, led by Vensana Capital and RC Capital, with participation from existing investors, will contribute to the development and commercialization of Elucent’s EnVisio and Smart Clip technologies.
Related: Nectero Medical closes $96M Series D
“We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures,” says Jason Pesterfield, president and CEO of Elucent Medical.
Elucent’s EnVisio is currently optimized to guide the surgical treatment of breast cancer, with adoption of the technology expanding to address other soft tissue oncology surgeries. Elucent is also currently developing products to assist surgeons in resections in lung and other soft tissue clinical applications; these products integrate with existing tools and minimally invasive solutions, including video and robotic-assisted medical technologies.
New board members Greg Banker and Kirk Nielsen of Vensana Capital and Scott Steever of RC Capital said, “We are excited to partner with the company to support their efforts to establish themselves as the market leader in breast navigation and to complete the development and launch of products in lung and other soft-tissue applications.”
